Adrestia Therapeutics enters new phase with Proteros partnership and appointment of head of chemistry

Published by
Cambridge Independent

By paul.brackley@iliffemedia.co.uk (Paul Brackley) Adrestia Therapeutics has entered into a multi-target partnership with German drug discovery company Proteros biostructures GmbH and announced the appointment of a head of chemistry. The Babraham Research Campus company, which is pioneering synthetic rescue therapies, says the developments signal a new phase as it aims to take its portfolio of validated targets into drug discovery for genetically defined neurologic and cardiomyopathic diseases. Its deal with Munich-based Proteros, a privately-held company with expertise in structure-based drug…

Read More

See also  ‘It’s so frustrating:’ Xfinity users face aggravation as internet outage affects Chicago area, multiple states

Leave a Reply